*LRB10410584LAW20660r*First SR0105Regular LRB104Session 10584Seventy-second LAWGeneral 20660Assembly rSTATE SENATEOF RESOLUTIONCOLORADO WHEREAS,ENGROSSED SeriousLLS mentalNO. illnesses like bipolar disorder, major depressive disorder, and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates continue to rise;

andR19-0909.01 WHEREAS,Rebecca WhileHausmann prolongedx2172 antipsychoticSJR19-007 useSENATE maySPONSORSHIP beMoreno, essentialBridges,Fenberg,Fields,Gardner,Hill,Lundeen,Scott,Tate,Todd,WilliamsA., forWinter, theWoodward, treatmentCooke, ofCoram, certainCourt, conditions,Crowder, itDanielson, isDonovan, associatedFoote, withGarcia, tardiveGinal, dyskinesiaGonzales, (TD),Hisey, aHolbert, conditionLee, markedMarble, byPettersen, uncontrollable,Priola, abnormal,Rankin, andRodriguez, repetitiveSmallwood, movementsSonnenberg, ofStory, theZenzinger face,HOUSE torso,SPONSORSHIP limbs,Kraft-Tharp, orBuentello, extremities;Caraveo, Gray, Hooton, Landgraf, Lontine, McKean, Melton, Michaelson Jenet, Roberts, Titone, Valdez A., Valdez D.

andSenate WHEREAS,Committees PeopleHouse atCommittees higherSENATE riskJOINT ofRESOLUTION TD19-007 includeCONCERNING thoseDESIGNATION olderOF thanTHE 55FIRST years,FULL peopleWEEK whoOF areM Black,AY women,AS individuals"T withARDIVE moodD orYSKINESIA substanceA useWARENESS disorders,W intellectualEEK disabilities,". or central nervous system injuries, and those with high cumulative antipsychotic exposure;

WHEREAS, Many people with serious, chronic mental illness, such as schizophrenia and WHEREAS,other Approximatelyschizoaffective 60%disorders, ofbipolar thedisorder, estimatedor 800,000severe U.S.depression, require treatment with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics;

adultsand livingWHEREAS,Whileongoingtreatmentwiththesemedicationscan withbe TDvery remainhelpful, undiagnosed, and even mildlifesaving, TDfor symptomsmany canpeople beit stigmatizingcan andalso impairlead physical,to social,Tardive andDyskinesia emotional(TD); well-being, underscoring the urgency of early screening, detection, and intervention;

and SR0105 -2- LRB104 10584 LAW 20660 r WHEREAS, TheMany Americanpeople Psychiatricwho Associationhave recommendsgastrointestinal routinedisorders, TDincludinggastroparesis,nausea,andvomiting,alsorequiretreatmentwith screeningg inE theird clinical1 guidelinesA fore antipsychotic, treatment,N andl individualsi treatedShading withdenotes antipsychoticsHOUSE oramendment. experiencing abnormal movements should consult their health care providers to assess TD risk, receive TD screenings, and determine appropriate treatment together;

andDouble WHEREAS,underlining FDA-approveddenotes treatmentsSENATE foramendSei TDp canCapital provideletters optionsor forbold symptom& managementitalic andnumbers improvedindicate qualitynew ofmaterial lifeto forbe manyadded individualsto livingFxAsting withstatute. TD;

andDashes WHEREAS,through Thethe Generalwords Assemblyindicate candeletions encouragefrom TDexisting screeningstatute. education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings;

therefore,DRBAs; be it RESOLVED, BY THE SENATE OF THE ONE HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 4 through May 10, 2025 as Tardive Dyskinesia Awareness Week (TDAW) in the State of Illinois;

and beWHEREAS,TreatmentofgastrointestinaldisorderswithDRBAs itcan furtherbe RESOLVED,very Thathelpful, webut support TDAW in recognition of the importance of early detection and intervention to improve SR0105 -3- LRB104 10584 LAW 20660 r outcomes for peoplemany livingpatients withcan mentallead health conditions and prescribed antipsychotics, and we support efforts to raiseTD; awareness about the causes and symptoms of tardive dyskinesia (TD) and the importance of routine TD screening.

and WHEREAS, TD is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities;

and WHEREAS, In some cases, people with TD experience involuntary and uncontrolled movement of the arms, legs, fingers, toes, tongue, lips, or jaw;

swaying movements of the trunk or hips;

or impacts tothemusclesassociatedwithwalking,speech,eating,andbreathing;and WHEREAS, TD can develop months, years, or decades after a person starts taking DRBAs, and even after the person has discontinued use of such medications;

and WHEREAS, Not everyone who takes a DRBA develops TD, but if TD develops it is often permanent;

and WHEREAS, Common risk factors for TD include advanced age, alcoholism,substanceabusedisorders,beingpostmenopausal,andmood disorders;

and WHEREAS,ApersonisathigherriskforTDaftertakingDRBAs for three months or longer, and the longer a person takes DRBAs, the higher the risk of developing TD;

and WHEREAS,StudiessuggestthattheoverallriskofdevelopingTD following prolonged exposure to DRBAs is between 10 and 30 percent;

and WHEREAS,Itisestimatedthatapproximately500,000individuals in the United States suffer from TD;

and WHEREAS, Years of challenging research have resulted in scientific advancements since 2017, with two new treatments for TD approved by the United States Food and Drug Administration;

and WHEREAS,TDisoftenunrecognizedandpatientssufferingfrom the illness are commonly misdiagnosed;

and -2- 007 WHEREAS, Patients taking DRBAs should see their health care providers for regular evaluations to ensure that any signs of TD are recognized;

and WHEREAS, Patients with TD often suffer embarrassment due to abnormal and involuntary movements, which leads them to withdraw from society and isolate themselves as the disease progresses;

and WHEREAS, The caregivers of patients with TD face many challenges and are often responsible for the overall care of the TD patient;

now, therefore, Be It Resolved by the Senate of the Seventy-second General Assembly of the State of Colorado, the House of Representatives concurring herein:

ThatthefirstfullweekofMayisproclaimed"TardiveDyskinesia Awareness Week", with the goals of:

(1) Raising awareness of this potentially debilitating disease;

(2) Encouraging individuals notafflictedwithTDtoconsiderthe effects of TD on individuals and society;

and (3) Encouraging Coloradans to contribute to charities supporting TD research and awareness.

BeItFurtherResolved,ThatcopiesofthisJointResolutionbesent to the Colorado chapter of the National Alliance on Mental Illness, MentalHealthColorado,theColoradoGovernor'soffice,theDepartment of Health Care Policy and Financing, the Department of Public Health and Environment, the Office of Saving People Money on Health Care, and the office of the Ombudsman for Behavioral Health Access to Care.

-3- 007